10x Genomics (TXG) Receivables (2018 - 2026)

10x Genomics (TXG) has 9 years of Receivables data on file, last reported at $20.9 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables fell 60.22% year-over-year to $20.9 million; the trailing twelve-month figure through Mar 2026 stood at $20.9 million (down 60.22% YoY), and the FY2025 full-year result was $82.5 million, down 6.75% from the prior year.
• Receivables declined to $20.9 million in Q1 2026, from $82.5 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $119.1 million in Q2 2025 to a low of $20.9 million in Q1 2026.
• A 5-year average of $85.3 million and a median of $87.7 million in 2023 frame the typical range for Receivables.
• Across the five-year window, Receivables surged 33.3% in 2022 and sank 60.22% in 2026, its largest moves.
• Tracing TXG's Receivables over 5 years: stood at $104.2 million in 2022, then grew by 10.19% to $114.8 million in 2023, then dropped by 23.49% to $87.9 million in 2024, then declined by 6.11% to $82.5 million in 2025, then sank by 74.66% to $20.9 million in 2026.
• Business Quant data shows TXG's Receivables at $20.9 million in Q1 2026, $82.5 million in Q4 2025, and $96.6 million in Q3 2025.